Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases
© Kuroda et al; licensee BioMed Central Ltd. 2006
Received: 12 June 2006
Accepted: 22 September 2006
Published: 22 September 2006
Oncolytic herpes simplex virus (HSV) vectors that specifically replicate in and kill tumor cells sparing normal cells are a promising cancer therapy. Traditionally, recombinant HSV vectors have been generated through homologous recombination between the HSV genome and a recombination plasmid, which usually requires laborious screening or selection and can take several months. Recent advances in bacterial artificial chromosome (BAC) technology have enabled cloning of the whole HSV genome as a BAC plasmid and subsequent manipulation in E. coli. Thus, we sought a method to generate recombinant oncolytic HSV vectors more easily and quickly using BAC technology.
We have developed an HSV-BAC system, termed the Flip-Flop HSV-BAC system, for the rapid generation of oncolytic HSV vectors. This system has the following features: (i) two site-specific recombinases, Cre and FLPe, are used sequentially to integrate desired sequences and to excise the BAC sequences, respectively; and (ii) the size of the HSV-BAC-insert genome exceeds the packaging limit of HSV so only correctly recombined virus grows efficiently. We applied this to the construction of an HSV-BAC plasmid that can be used for the generation of transcriptionally-targeted HSV vectors. BAC sequences were recombined into the UL39 gene of HSV ICP4-deletion mutant d120 to generate M24-BAC virus, from which HSV-BAC plasmid pM24-BAC was isolated. An ICP4 expression cassette driven by an exogenous promoter was re-introduced to pM24-BAC by Cre-mediated recombination and nearly pure preparations of recombinant virus were obtained typically in two weeks. Insertion of the ICP4 coding sequence alone did not restore viral replication and was only minimally better than an ICP4-null construct, whereas insertion of a CMVIE promoter-ICP4 transgene (bM24-CMV) efficiently drove viral replication. The levels of bM24-CMV replication in tumor cells varied considerably compared to hrR3 (UL39 mutant).
Our Flip-Flop HSV-BAC system enables rapid generation of HSV vectors carrying transgene inserts. By introducing a tumor-specific-promoter-driven ICP4 cassette into pM24-BAC using this system, one should be able to generate transcriptionally-targeted oncolytic HSV vectors. We believe this system will greatly facilitate the screening of a plethora of clinically useful tumor-specific promoters in the context of oncolytic HSV vectors.
Oncolytic virus therapy is a new modality of cancer treatment, which has shown promising results in clinical trials . Oncolytic viruses are designed to selectively replicate in and kill cancer cells without harming normal tissue. Since reporting the successful treatment of a brain tumor model by a tk-mutant herpes simplex virus (HSV) vector in 1991 , we have focused on the development of increasingly efficacious and safe, replication-competent oncolytic HSV vectors. For the generation of new oncolytic vectors, insertion of exogenous genes or promoter sequences is often performed to enhance anti-tumor activity or tumor-selectivity of the vector. An example of the former is insertion of an interleukin gene and of the latter, insertion of a tumor- or tissue-specific promoter [3, 4]. Traditionally, recombinant HSV vectors have been generated through homologous recombination by co-transfecting mammalian cells with purified HSV DNA and a plasmid containing exogenous sequences flanked by viral sequences homologous to the insertion site. This method usually requires laborious screening or selection and can take several months. Recent advances in bacterial artificial chromosome (BAC) technology have enabled cloning of the whole HSV genome as a BAC plasmid and subsequent manipulation in E. coli [5–8]. Thus, we sought a method to generate recombinant oncolytic HSV vectors more easily and quickly using BAC technology.
It is not practical to manipulate BAC-cloned HSV DNA using conventional subcloning methods such as restriction enzyme digestion and ligation, because HSV-BAC DNA is usually more than 150 kilobases (kb) in length. To circumvent this problem and achieve efficient and accurate manipulation in E. coli, site-specific recombination (e.g. Cre/loxP system), homologous recombination/allelic exchange (e.g. RecA, RecE/T, bacteriophage λ red system), and transposon integration have been used for mutagenesis or the introduction of foreign sequences into BAC-cloned virus genomes [6, 8–16]. Another factor to consider in BAC-mediated recombinant HSV construction is the packaging capacity of the HSV virion. It has been reported that packaging of DNA fragments larger than 156 kb into HSV virions is not efficient [17, 18]. BAC cloning requires insertion of mini F plasmid sequences and antibiotic resistance genes into the viral genome and the length of these BAC backbone sequences is usually greater than 6 kb in total . Insertion of BAC sequences into the wild-type HSV genome (152 kb) will increase the genome length to ~158 kb, and there will be no space left for the insertion of additional sequences. To avoid deleterious effects of the BAC sequences, including growth defects and potential transmission between bacteria and man, some herpesvirus BAC clones have been constructed with loxP site-flanked BAC sequences, which can be removed by Cre recombinase [8, 20, 21]. In this study, we chose to use two independent site-specific recombination systems, Cre/loxP and FLP/FRT, sequentially in two separate steps. These two steps are: (i) integration of the shuttle vector containing a foreign sequence into the HSV-BAC genome and (ii) excision of the BAC sequences from the integrated HSV-BAC-shuttle DNA. We also employed another strategy for efficient generation of correctly recombined HSV vectors. The size of the integrated HSV-BAC-shuttle DNA was designed to exceed the packaging capacity of the HSV virion by inserting a stuffer sequence, so that recombinant HSV genomes are efficiently packaged and propagated only after removal of the BAC and stuffer sequences by FLPe. This strategy enabled us to obtain nearly pure (>99%) preparations of correctly recombined virus lacking the BAC sequences by simply co-transfecting mammalian cells with the integrated HSV-BAC-shuttle vector and an FLPe expression plasmid. We termed this system the Flip-Flop (FLP/FRT and Cre/loxP mediated) HSV-BAC system.
In this paper, we describe the Flip-Flop HSV-BAC system and its use for the generation of recombinant HSV vectors with the essential ICP4 gene driven by the CMVIE promoter. ICP4 (infected cell protein 4) is the product of the immediate-early α4 or IE-3 gene, and functions as the main transcriptional activator of viral genes [22, 23]. Previously, we reported the generation of transcriptionally-targeted oncolytic HSV vectors using an ICP4-deletion mutant HSV d120 as a backbone . We introduced an albumin-promoter-driven ICP4 expression cassette into the tk gene locus of d120 and showed that the resultant virus G92A selectively replicated in and killed hepatoma cells and tumor xenografts in which the albumin promoter was active . Using the same strategy, another group generated an oncolytic HSV vector targeting soft tissue and bone tumors with an ICP4 cassette driven by human calponin promoter . For the present study, we cloned d120 as a BAC plasmid, with the BAC sequences integrated in the UL39 (ICP6) gene, and then inserted ICP4 expression cassettes into d120-BAC using the Flip-Flop HSV-BAC system. ICP6 is the large subunit of viral ribonucleotide reductase and disruption of this gene limits HSV growth to actively dividing cells [26–28]. We showed that insertion of an ICP4 expression cassette driven by the CMVIE promoter efficiently drove viral replication, whereas insertion of the ICP4 coding sequence (CDS) alone did not restore viral replication. Use of a tumor-specific promoter instead of the CMVIE promoter, should generate a transcriptionally-targeted oncolytic HSV vector. Furthermore, these studies illustrate the power of the Flip-Flop HSV-BAC system to rapidly generate HSV recombinants.
Outline of the Flip-Flop HSV-BAC system
In the first step, the shuttle vector pFLS-Pr is integrated into pM24-BAC by Cre recombinase in vitro and an integrated BAC clone (pM24-BAC-shuttle) isolated in E. coli by selection with kanamycin and chloramphenicol. As replication from the R6Kγ origin is dependent on the π protein encoded by the pir gene and the BAC host E. coli strain is pir-, the R6Kγ origin in the integrated BAC does not interfere with BAC replication . In the second step, the integrated pM24-BAC-shuttle DNA and the FLPe expression plasmid are co-transfected to ICP4-complementing E5 cells and the BAC backbone and stuffer sequences, flanked by FRT sites derived from pM24-BAC and the shuttle vector, are excised by FLPe recombinase (Fig 1). Any HSV genome retaining the BAC sequences (from the original pM24-BAC-shuttle DNA) is oversized and cannot be packaged efficiently.
Cloning of the prototype HSV-BAC clone pM24-BAC
An HSV-BAC plasmid containing the whole genome of M24-BAC, pM24-BAC, was isolated by transforming DH10B E. coli with circular viral DNA and its genomic structure confirmed by HindIII restriction analysis (Fig 3; right panel). pM24-BAC DNA was infectious, generating virus, bM24-BAC (b refers to BAC/bacterial derived virus) after transfection of E5 cells. Two independent plaque-purified bM24-BAC isolates and parental M24-BAC had similar properties: (i) they formed comparably sized EGFP-positive plaques; (ii) they had identically sized restriction endonuclease fragments [see Additional file 1]; and (iii) they had identical virus growth kinetics and similar virus yields [see Additional file 2]. Therefore, we concluded that the reconstituted bM24-BAC virus retains the same characteristics as the original M24-BAC virus and that the HSV-BAC plasmid pM24-BAC contains a faithful copy of the M24-BAC virus genome.
Shuttle vector integration into pM24-BAC by Cre recombinase
List of recombinant viruses and shuttle and BAC plasmid clones used for their generation
BAC-derived recombinant virus
ICP4 expression cassette on the vector
Integrated pM24-BAC-shuttle clone
The CMV promoter drives the ICP4 expression.
No active promoter drives the ICP4 expression.
No ICP4 CDS included on the vector. (A shuttle vector containing no ICP4 CDS was constructed)
pM24-BAC (Non-integrated prototype HSV-BAC)
Genetically identical to the prototype HSV-BAC virus M24-BAC
Recombinant virus generation by FLPe recombinase excision of BAC sequences
The recombinant viruses replicate efficiently only when ICP4 is expressed
Transcriptionally-targeted oncolytic virus vectors are promising cancer therapeutic agents and some of them have already been applied to cancer patients in clinical trials. For example, an oncolytic adenovirus vector CV706 whose replication is driven by the prostate-specific antigen (PSA) promoter/enhancer element has completed Phase I clinical trials and some of the patients showed a significant decrease in serum PSA levels . Although there are many potentially promising tumor-specific promoters reported in the literature and many of them have been used for generation of oncolytic adenoviruses , only a few have been tested in the context of transcriptionally-targeted HSV vectors due to the extensive labor involved in constructing recombinant HSV vectors [4, 25, 32].
Traditionally, recombinant HSV vectors have been generated via homologous recombination between purified HSV DNA and recombination plasmid in co-transfected cells. In addition to the inefficiency of recombination, there is the need to screen or select plaques for the correct recombinant. This has hampered the development of new recombinant HSV vectors. Recent advances in BAC technology have enabled the cloning of herpesvirus genomes as BACs and their manipulation in E. coli [5–14, 16, 20, 21]. Using our Flip-Flop HSV-BAC system, once a shuttle vector containing a promoter of interest is constructed, nearly pure (>99%) preparations of recombinant vector can be obtained typically within two weeks, which can be easily plaque-purified subsequently. It should be noted that this system can also be applied to the generation of transgene-expressing HSV vectors if replication-competent HSV-BAC is used as a prototype BAC . A similar strategy for the generation of oncolytic HSV vectors, termed the HSVQuik system, has recently been reported .
In Step1 of the Flip-Flop HSV-BAC system, Cre-mediated recombination was performed biochemically and then integrated BAC DNA electroporated into E. coli. As high-molecular-weight BAC DNA is vulnerable to mechanical shearing, these procedures could cause double-strand breaks, lowering the proportion of correctly integrated HSV-BACs. When we generated pM24-BAC-null clones, more than half of the clones (7 out of 13) had suffered large deletions occurring at random locations (Fig 4b), while for pM24-BAC-CMV and pM24-BAC-null cloning, 90% (9 out of 10) of the BAC clones contained a full-length HSV-BAC genome, with either single or multiple shuttle inserts (Fig 4a and data not shown). To date, we have generated several different transcriptionally-targeted HSV vectors using this system and found that the efficiency of full-length HSV-BAC cloning after Cre recombination varied between 40 to 100% (average 69%; 67 complete clones out of 97 clones) (TK, unpublished data). An alternate way to avoid BAC DNA shearing in Step1 would be to perform site-specific recombination in bacteria by introducing the shuttle and Cre-expressing plasmids into the E. coli carrying the prototype HSV-BAC plasmid, as reported previously . Terada et al. employed, in their HSVQuik system, a similar strategy using an FLP-expressing plasmid for the integration of their HSV-BAC and transfer plasmids, and reported that ~80% of HSV-BAC clones contained correct co-integrants .
The efficiency of FLPe-mediated excision of the BAC and stuffer sequences from the integrated HSV-BAC-shuttle DNA was high, with over 99% of recombinant virus harvested after Step2 LacZ-positive and EGFP-negative. In order for recombined virus to be generated, several events need to occur: (i) both the integrated HSV-BAC-shuttle and the FLPe plasmid is transfected into a same cell, (ii) FLPe is expressed, (iii) the BAC sequences are excised from the HSV-BAC DNA, (iv) the recombined viral genome is replicated and (v) packaged. There are multiple factors affecting these processes, including the rate and level of FLPe expression and the timing of recombination. In fact, we do not know at which stage the FLPe recombination occurs, i.e. in the original HSV-BAC DNA or in the replicated virus DNA concatemer. In the former case, all the replicated viral DNA are correct recombinants and readily packaged, whereas in the latter case, only a fraction of the viral DNA concatemer may be packaged. Therefore, the efficiency of viral production through all these events could be lower than that after transfection of pM24-BAC alone, from which bM24-BAC virus can be generated directly without recombination. In our experiment, the yield of FLPe-recombined virus was sufficient, albeit a log lower than that of bM24-BAC (Fig 5b). For the generation of bM24-empty virus, we used pM24-BAC-empty clones that contained multiple integrated copies of shuttle vector. Even in these multiple inserts, FLPe recombination between the most distal pair of FRT sites results in the generation of correct recombinant virus, while recombination between other pairs of FRT sites generates viral genomes, which are still oversized and cannot be efficiently packaged. Thus, multiple-insert BAC clones can be used for recombinant virus generation.
When pM24-BAC-null was co-transfected with the FLPe plasmid to excise the BAC sequences, the ratio of bM24-null to bM24-BAC-null was over 300 (Fig 5b). There are two factors affecting the final yield ratio between the recombined and non-recombined virus: (i) efficiency of recombination, and (ii) difference in growth kinetics between the two viruses. Previously, Smith and Enquist, reported that co-transfection of loxP-carrying PRV-BAC DNA and a Cre expression plasmid resulted in a virus preparation containing 10–15% non-recombined viruses . In order to improve the yield of correctly recombined virus, they inserted a Cre expression cassette into the loxP-flanked BAC cassette so that Cre was expressed from non-recombined BAC-virus. This self-excision strategy worked very well and the yield of correctly recombined virus was more than 99.9%. In the Flip-Flop HSV-BAC system, we took a different approach to maximize the yield of correct recombinant virus; a stuffer sequence was included in the shuttle vector so that the integrated HSV-BAC clones are oversized and produce virus efficiently only after the BAC and stuffer sequences are removed. Using this strategy, ~99.7% of harvested viruses were correct recombinants (Fig 5b). As shown in Fig 5c, the growth of oversized bM24-BAC-null virus (~166 kb) was much reduced compared to that of recombined virus bM24-null. As HSV-BAC can accommodate larger DNA, an integrated HSV-BAC with a much larger genome size (e.g. >180 kb) using a longer stuffer sequence, should further reduce the production of non-recombined virus.
We previously reported the generation of albumin-promoter-driven HSV vector G92A in which the ICP4 expression cassette was inserted into the thymidine kinase (tk) gene . Unfortunately, tk-mutant viruses are resistant to acyclovir treatment, which is not desirable for clinical application . To avoid this problem, we chose to insert the BAC vector sequences and ICP4 expression cassette into the UL39 gene, preserving the tk gene. UL39 encodes ICP6, the large subunit of the viral ribonucleotide reductase, and its inactivation limits vector replication to actively dividing cells [26–28]. Additionally, ICP6 inactivation increases virus sensitivity to acyclovir [37, 38]. It is worth noting that the initial HSV-BAC construct can be generated by insertion of the BAC cassette into any desired sequence or gene in the viral genome, other than ICP6.
In the current study, it was important to first demonstrate that there were not cryptic regulatory sequences that would drive ICP4 expression in the absence of promoters when inserted into the ICP6 region of HSV. bM24-null is such a construct and was highly defective in replication, only minimally better than bM24-empty, lacking any ICP4 sequences. These results show that pM24-BAC is suitable as a prototype construct for the generation of transcriptionally-targeted HSV vectors. In a plaquing assay, bM24-null formed a few plaques on Vero cells when infected at 10000 pfu/well, while no plaques were formed by the same amount of bM24-empty (Fig 7b). These plaques might have arisen from bM24-null mutants with genome rearrangements or deletions that activated ICP4 expression.
When ICP4 was expressed under the control of the CMVIE promoter, its level of expression was much lower than KOS and hrR3, which have diploid copies of wild-type ICP4 gene (Fig 7a). Recently, Terada et al. reported that HSV promoters, ICP6, IE2 and IE4/5, induced a higher level of luciferase expression compared to the CMVIE promoter when inserted in the ICP6 gene , the same location as in bM24-CMV. Regulation of HSV transcription and translation is complex, with ICP4 playing a major role, both as a trans-activator and repressor . Upon infection, the tegument protein VP16 activates HSV immediate-early gene expression, however it does not similarly activate the CMVIE promoter , which could account for the delayed kinetics. In a study of CMVIE promoter-GFP expression in HSV immediate-early gene mutants, it was found that CMVIE promoter activity was dependent upon ICP0 expression levels  and that the CMVIE promoter in the HSV genome was actively repressed in the absence of viral activators .
It is not clear what levels of ICP4 expression are necessary for viral replication. In a single-step growth assay (Fig 8a,b), bM24-CMV grew efficiently in Vero cells, with slower kinetics than hrR3 or KOS, presumably reflecting the lower and slower induction of ICP4 by the CMVIE promoter. Furthermore, the levels of bM24-CMV replication, as opposed to hrR3, varied considerably in different tumor cell lines. This could be due to variable activity of the CMVIE promoter or different levels of ICP4 required for replication in different cell lines. In fact, we found that the transcriptional activity of the CMVIE promoter in SW480 was 3 to 8 fold lower than in HepG2 or A549, using a transient luciferase reporter assay . While considered constitutive, CMVIE promoter activity has been shown to vary greatly in different cells; in transgenic mice, or with transiently transfected plasmids or adenovirus vectors [43–46].
The Flip-Flop HSV-BAC system we describe enables rapid generation of HSV vectors carrying transgene inserts. By introducing a tumor-specific-promoter-driven ICP4 cassette into pM24-BAC using this system, one should be able to generate transcriptionally-targeted oncolytic HSV vectors. We believe this system will greatly facilitate the screening of a plethora of clinically useful tumor-specific promoters in the context of oncolytic HSV vectors.
Cells and viruses
Vero (African Green Monkey kidney cells), SW480 (Human colon adenocarcinoma), and HepG2 (Human hepatoblastoma) cells were obtained from American Type Culture Collection (Manassas, VA). A549 (Human lung adenocarcinoma) cells were provided by W. Kallas (Massachusetts General Hospital, Boston, MA). E5 cells are Vero cells stably transfected with HSV ICP4, so they express complementing levels of wild type ICP4 upon HSV-1 infection and were provided by N. DeLuca (University of Pittsburgh School of Medicine, Pittsburgh, PA) . Vero and E5 cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% calf serum and other cell lines in DMEM supplemented with 10% fetal calf serum. Wild-type HSV-1 strain KOS was provided by D. Knipe (Harvard Medical School, Boston, MA), ICP6- recombinant hrR3 (parental strain KOS) was provided by S. Weller (University of Connecticut Health Center, Farmington, CT) , and ICP4 deletion mutant d120 (parental strain KOS) was provided by N. DeLuca . Virus stocks were generated from low-multiplicity infections.
pCAGGS-FLPe was provided by Dr. P. Lowenstein (Cedars-Sinai Hospital, Los Angeles, CA) . Other plasmids were constructed as follows. The recombination plasmid, pBAC-ICP6EF: AscI-tagged ICP6 CDS was generated via PCR from d120 DNA using the LA-PCR kit (TaKaRa Mirus Bio, Madison, WI) and 5'-TATGGCGCGC CAACCCGCCG CGTCTGTTGA AAT-3' (sense) and 5'-ATAGGCGCGC CTTTGTCGGT CACAGCGCGC AGCTC-3' (antisense) primers. The PCR product was digested with AscI, ligated, and digested again with XhoI and StuI. The resultant 2556 bp fragment containing 3' (1.2 kb) and 5' (1.3 kb) fragments of the ICP6 CDS ligated tail-to-head was subcloned into the XbaI/XhoI sites of pBluescriptII-KS+ vector (Stratagene, La Jolla, CA) to create pBS2ICP6TH. The EGFP CDS excised from pEGFP-N1 (Clontech, Palo Alto, CA) was subcloned into the HindIII/AgeI sites of pVP22/myc-His2 vector (Invitrogen, Carlsbad, CA) to create pCMV-EGFP. pCMV-EGFP2 was created by digestion of pCMV-EGFP with PvuII and subsequent self-ligation. Two oligomers containing the FRT recognition sequence (underlined), CGCGCGAAGT TCCTATACTT TCTAGAGAAT AGGAACTTCC TCGAG (sense) and AATTCTCGAG GAAGTTCCTA TTCTCTAGAA AGTATAGGAA CTTCG (antisense) were synthesized, hybridized and subcloned into the MluI/MfeI sites of pCMV-EGFP2 to create pEGFP-FRT. The FRT recognition site followed by the EGFP expression cassette driven by the CMV promoter with the BGH polyA signal was excised from pEGFP-FRT by XhoI and PciI digestion and subcloned into the XhoI/PciI sites of pBSICP6TH to create pICP6TH-EF. Finally, the NotI/PvuII digestion fragment of pICP6TH-EF containing the EGFP cassette, the FRT site and the 3' and 5' fragments of the ICP6 CDS was subcloned into the NotI/SrfI sites of pBelobac11 (Research Genetics, Huntsville, AL) to create pBAC-ICP6EF. The promoterless shuttle vector, pFLS-ICP4: Two oligomers containing the loxP recognition sequence (underlined), AGCTTATAAC TTCGTATAAT GTATGCTATA CGAAGTTATC CATGGCTGCA (sense) and GCCATGGATA ACTTCGTATA GCATACATTA TACGAAGTTA TA (antisense) were synthesized, hybridized and subcloned into the HindIII/PstI sites of pUC18 to create pUC-loxP. Then the FRT sequence oligomers described above were subcloned into the BamHI/EcoRI sites of pUC-loxP to create pUC-LF, which was subsequently digested with HindIII and NdeI, filled-in and self-ligated to create pUC-LF2. pCMV-LacZV was constructed from pcDNA6-E/Uni-lacZ (Invitrogen) by AgeI and PmlI digestion followed by self-ligation. The NcoI/SalI fragment of pCMV-LacZV containing the LacZ CDS and V5 epitope tag followed by the SV40 polyA signal was subcloned into the NcoI/SalI sites of pUC-LF2 to create pLLZF2. Two oligomers containing a MCS sequence, GATCAGTACT AGTCCTGCAG GCTTAAGGGT ACCGCTAGCA TTTAAATGTC GACAGGCC (sense) and TCGAGGCCTG TCGACATTTA AATGCTAGCG GTACCCTTAA GCCTGCAGGA CTAGTACT (antisense), were synthesized, hybridized and subcloned into the BamHI/SalI site of pLLZF2 to create pLLZMF2. The 4.1-kb SalI/MseI fragment of pGH108 (provided by G. Hayward, Johns Hopkins School of Medicine, Baltimore, MD)  containing the ICP4 CDS was subcloned into the StuI/SalI sites of pLLZMF2 to create pLLZMF2-ICP4. To generate a stuffer sequence, the 4.0-kb AgeI-digest fragment of bacteriophage lambda DNA (nucleotide position 6562 – 10550) was obtained by digesting a HindIII digest of lambda DNA (New England Biolab, Beverly, MA). Subsequently, pUni-lmd was created by subcloning the stuffer sequence into the AgeI/XmaI sites of pUni/V5-HisA vector (Invitrogen) that contains the R6Kγ plasmid replication origin and kanamycin resistance gene. Finally, the 7.6-kb HindIII/XhoI fragment of pLLZMF2-ICP4 was subcloned into the NotI/XhoI sites of pUni-lmd to create pFLS-ICP4. pFLS-CMV: The CMV promoter was excised from pVP22/myc-His2 by KpnI and ScaI digestion and subcloned into the KpnI/NruI sites of the pFLS-ICP4 to create pFLS-CMV. pFLS2: An oligomer containing the NotI recognition sequence, 5'-AGCTCATAGCGGCCGCTATG-3', was synthesized, hybridized and subcloned into the HindIII site of pLLZMF2 to create pLLZMF2N. The 3.5-kb NotI/XhoI digestion fragment of pLLZMF2N was subcloned into the NotI/XhoI sites of pUni-lmd to create pFLS2.
For mammalian cell transfection, plasmid DNA, including BAC, was purified using a plasmid purification kit (QIAGEN, Valencia, CA) following manufacturer's protocols.
Monolayer cultures of Vero cells (for KOS and hrR3) or E5 cells (for ICP4 mutant viruses) grown in six-well dishes were infected with serial dilutions of virus. After removal of virus inoculum, the cells were incubated in DMEM supplemented with 1% IFCS and 0.1% pooled human immune globulin (BayGam; Bayer Corporation, Elkhart, IN) at 37°C for 3 to 4 days until plaques were visible. The cells were fixed with methanol (for Giemsa staining), or 0.5% glutaraldehyde-2% paraformaldehyde (for X-Gal histochemistry). Plaques were counted and the average number of plaques was determined from 2 wells. To count EGFP-positive plaques, cells were observed under an inverted fluorescence microscope without fixation.
Generation of M24-BAC virus
d120 viral DNA was purified as previously described . Briefly, confluent monolayers of E5 cells were infected with d120 virus at a multiplicity of infection (MOI) of 2, and 16 hours later, when total cytopathic effect (CPE) was observed, cells were harvested, pelleted by centrifugation, washed with Dulbecco's phosphate-buffered saline (PBS), resuspended in RS buffer (10 mM TrisHCl pH8, 10 mM KCl, 1.5 mM MgCl2), incubated on ice for 20 min, and homogenized with a Dounce homogenizer. After centrifugation at 1000 g, 4°C, 5 min, the pellet containing the nuclei was further lysed in RS buffer with 0.25% TritonX, centrifuged again and the supernatant combined with the initial supernatant, which was treated with Proteinase K (Invitrogen) and SDS at 37°C overnight. Viral DNA was purified by ultracentrifugation in a NaI density gradient .
E5 cells (1.8 × 105 cells/well) plated in six-well dishes were co-transfected with 250 ng of purified d120 DNA and 180 ng of AscI-digested pBAC-ICP6EF using lipofectamine PLUS (Invitrogen) following the manufacturer's protocol. Cells were harvested 5 days post-transfection when EGFP-positive plaques were observed. Recombinant viruses, identified as EGFP-positive plaques, were plaque purified on E5 cells by three rounds of limiting dilution.
Restriction analysis of viral DNA
Viral DNA for restriction analysis was purified as previously described with some modifications . Briefly, E5 cells plated in 10 cm culture dish was infected with virus and harvested when total CPE was observed. The cells were pelleted by centrifugation, resuspended in buffer (10 mM TrisHCl pH7.5, 10 mM NaCl, 3 mM MgCl2) and lysed by three freeze-thaw cycles. After centrifugation at 2000 g 4°C for 10 min, the supernatant was collected and treated with RNase A (QIAGEN) and DNase I (Sigma, St. Louis, MO) at 37°C for 2 hours, and subsequently treated with Proteinase K and SDS at 56°C overnight. Viral DNA was purified by phenol-chloroform extraction and ethanol precipitation. For restriction analysis, viral and BAC DNA was digested with Hind III and separated by electrophoresis in 0.5% agarose/Tris-acetate-EDTA buffer. A 1-kb DNA ladder (Invitrogen) and a high-molecular-weight DNA marker (Invitrogen) were used as molecular weight standards.
Cloning of a BAC clone containing the whole genome of M24-BAC virus
Isolation of a BAC clone containing the whole genome of M24-BAC virus was performed as reported previously . Briefly, Vero cells (6 × 105 cells/well) plated in six-well dishes were infected with M24-BAC at an MOI of 3. Cells were lysed 90 min after infection with 500 μl of lysis buffer (0.6% SDS, 10 mM EDTA pH 7.5) and incubated at room temperature for 20 min. Then 330 μl of 5 M NaCl was added to the lysate and the mixture was incubated on ice for 5 hours. After centrifugation at 16000 g for 20 min at 4°C, the supernatant (Hirt extract) was removed, DNA extracted with phenol/chloroform, ethanol precipitated, and dissolved in 5 μl of TE buffer. Electrocompetent DH10B cells (Invitrogen) were transformed with 2 μl of DNA using Gene Pulser II (Bio-Rad, Hercules, CA) and chloramphenicol resistant clones were isolated.
Integration of shuttle vectors with pM24-BAC by Cre recombinase
Site-specific recombination between pM24-BAC and shuttle vector DNA was performed as previously described with some modifications . Briefly, 1 to 1.5 μg of pM24-BAC and 150 ng of shuttle vector DNA were mixed with Cre recombinase (Invitrogen) in a total volume of 10 μl and incubated at 37°C for 1 h. Following heat-inactivation of Cre recombinase at 70°C for 10 min, recombined DNA was ethanol precipitated and dissolved in 5 μl of TE buffer or dH2O. Electrocompetent DH10B cells were transformed with 1 μl of DNA using Gene Pulser II and chloramphenicol/kanamycin double-resistant clones were isolated.
Recombinant virus production from integrated pM24-BAC-shuttle DNA
E5 cells (1.5 × 105 cells/well) plated in 24-well dishes were co-transfected with 1 μg of pM24-BAC-shuttle DNA and 100 ng of pCAGGS-FLPe using lipofectamine PLUS following manufacturer's protocol. 5 to 7 days after transfection, when CPE is observed, cells were harvested and lysed by three freeze/thaw cycles and sonication. Recombinant viruses were plaque purified on E5 cells by limiting dilution.
Monolayer cultures of cells in 12-well dishes were infected with the designated virus at an MOI of 3 in 350 μl of DMEM with 1%IFCS (for single step growth) or cells in 6-well dishes were infected with 1 × 104 pfu of the designated virus (MOI of ~0.01) in 0.7 ml of DMEM with 1%IFCS (for replication assay). The virus inoculum was removed after 2 hours and the cells were incubated in DMEM supplemented with 10% IFCS (or 1% IFCS for Vero cells) at 37°C in humidified 5% CO2. At the times indicated, virus was harvested from the wells and titers were determined on Vero cells (for KOS and hrR3) or on E5 cells (for other recombinant viruses).
Immunoblot analysis of ICP4
Monolayer cultures of cells grown in 12-well dishes were infected with the designated virus at an MOI of 2, as described above. At the times indicated, the cells were briefly washed with PBS and lysed with 1 × SDS sample buffer. Proteins obtained from ~3 × 104 infected cells were separated by SDS-PAGE (5% gel) and transferred to PVDF membrane (Immobilon-P, Millipore, Bedford, MA) using a tank transfer system (Bio-Rad). Membranes were blocked with 5% non-fat dry milk in TBST (10 mM Tris pH8, 150 mM NaCl, 0.1% Tween-20), washed in TBST, and probed with mouse anti-HSV-ICP4 monoclonal antibody (US Biological, Swampscott, MA) diluted in TBST (1:6000 dilution). After washing in TBST, the blot was probed with HRP-linked anti-mouse-IgG antibody (Amersham Biosciences, Piscataway, NJ). The membranes were washed in TBST and chemiluminescent detection was performed using the ECL Western Blotting Detection Reagents (Amersham Biosciences). Molecular weights were determined using prestained protein standards (Bio-Rad).
We would like to thank Drs Pedro Lowenstein and Gary Hayward for providing plasmids, Wendy Kallas and Neal DeLuca for cells and virus, David Knipe and Sandy Weller for virus, and Manish Aghi and Ta-chiang Liu for critical reading of the manuscript. We also thank Drs. Hiroshi Fukuhara and Yasushi Ino for helpful discussion. This work was supported in part by grants to RLM from NIH (R01 NS032677 and CA102139), and the Department of Defense (W81XWH-04-1-0254) and to TT from the James S. McDonnell Foundation Brain Cancer Program and the Massachusetts General Hospital/Giovanni Armenise Neuro-Oncology and Related Disorders Grants Program.
- Aghi M, Martuza RL: Oncolytic viral therapies - the clinical experience. Oncogene. 2005, 24: 7802-7816. 10.1038/sj.onc.1209037.View ArticleGoogle Scholar
- Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991, 252: 854-856. 10.1126/science.1851332.View ArticleGoogle Scholar
- Parker JN, Gillespie GY, Love CE, Randall S, Whitley RJ, Markert JM: Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A. 2000, 97: 2208-2213. 10.1073/pnas.040557897.View ArticleGoogle Scholar
- Miyatake S, Iyer A, Martuza RL, Rabkin SD: Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol. 1997, 71: 5124-5132.Google Scholar
- Stavropoulos TA, Strathdee CA: An enhanced packaging system for helper-dependent herpes simplex virus vectors. J Virol. 1998, 72: 7137-7143.Google Scholar
- Horsburgh BC, Hubinette MM, Qiang D, MacDonald ML, Tufaro F: Allele replacement: an application that permits rapid manipulation of herpes simplex virus type 1 genomes. Gene Ther. 1999, 6: 922-930. 10.1038/sj.gt.3300887.View ArticleGoogle Scholar
- Saeki Y, Ichikawa T, Saeki A, Chiocca EA, Tobler K, Ackermann M, Breakefield XO, Fraefel C: Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther. 1998, 9: 2787-2794.View ArticleGoogle Scholar
- Tanaka M, Kagawa H, Yamanashi Y, Sata T, Kawaguchi Y: Construction of an excisable bacterial artificial chromosome containing a full-length infectious clone of herpes simplex virus type 1: viruses reconstituted from the clone exhibit wild-type properties in vitro and in vivo. J Virol. 2003, 77: 1382-1391. 10.1128/JVI.77.2.1382-1391.2003.View ArticleGoogle Scholar
- Adler H, Messerle M, Wagner M, Koszinowski UH: Cloning and mutagenesis of the murine gammaherpesvirus 68 genome as an infectious bacterial artificial chromosome. J Virol. 2000, 74: 6964-6974. 10.1128/JVI.74.15.6964-6974.2000.View ArticleGoogle Scholar
- Hahn G, Khan H, Baldanti F, Koszinowski UH, Revello MG, Gerna G: The human cytomegalovirus ribonucleotide reductase homolog UL45 is dispensable for growth in endothelial cells, as determined by a BAC-cloned clinical isolate of human cytomegalovirus with preserved wild-type characteristics. J Virol. 2002, 76: 9551-9555. 10.1128/JVI.76.18.9551-9555.2002.View ArticleGoogle Scholar
- Smith GA, Enquist LW: Construction and transposon mutagenesis in Escherichia coli of a full-length infectious clone of pseudorabies virus, an alphaherpesvirus. J Virol. 1999, 73: 6405-6414.Google Scholar
- Strathdee CA: Transposing BACs to the future. Nat Biotechnol. 1999, 17: 332-333. 10.1038/7884.View ArticleGoogle Scholar
- Schumacher D, Tischer BK, Fuchs W, Osterrieder N: Reconstitution of Marek's disease virus serotype 1 (MDV-1) from DNA cloned as a bacterial artificial chromosome and characterization of a glycoprotein B-negative MDV-1 mutant. J Virol. 2000, 74: 11088-11098. 10.1128/JVI.74.23.11088-11098.2000.View ArticleGoogle Scholar
- Messerle M, Crnkovic I, Hammerschmidt W, Ziegler H, Koszinowski UH: Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc Natl Acad Sci U S A. 1997, 94: 14759-14763. 10.1073/pnas.94.26.14759.View ArticleGoogle Scholar
- Domi A, Moss B: Engineering of a vaccinia virus bacterial artificial chromosome in Escherichia coli by bacteriophage lambda-based recombination. Nat Methods. 2005, 2: 95-97. 10.1038/nmeth734.View ArticleGoogle Scholar
- White RE, Calderwood MA, Whitehouse A: Generation and precise modification of a herpesvirus saimiri bacterial artificial chromosome demonstrates that the terminal repeats are required for both virus production and episomal persistence. J Gen Virol. 2003, 84: 3393-3403. 10.1099/vir.0.19387-0.View ArticleGoogle Scholar
- Wade-Martins R, Saeki Y, Chiocca EA: Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. Mol Ther. 2003, 7: 604-612. 10.1016/S1525-0016(03)00060-1.View ArticleGoogle Scholar
- Wade-Martins R, Smith ER, Tyminski E, Chiocca EA, Saeki Y: An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat Biotechnol. 2001, 19: 1067-1070. 10.1038/nbt1101-1067.View ArticleGoogle Scholar
- Shizuya H, Birren B, Kim UJ, Mancino V, Slepak T, Tachiiri Y, Simon M: Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coli using an F-factor-based vector. Proc Natl Acad Sci U S A. 1992, 89: 8794-8797. 10.1073/pnas.89.18.8794.View ArticleGoogle Scholar
- Adler H, Messerle M, Koszinowski UH: Virus reconstituted from infectious bacterial artificial chromosome (BAC)-cloned murine gammaherpesvirus 68 acquires wild-type properties in vivo only after excision of BAC vector sequences. J Virol. 2001, 75: 5692-5696. 10.1128/JVI.75.12.5692-5696.2001.View ArticleGoogle Scholar
- Smith GA, Enquist LW: A self-recombining bacterial artificial chromosome and its application for analysis of herpesvirus pathogenesis. Proc Natl Acad Sci U S A. 2000, 97: 4873-4878. 10.1073/pnas.080502497.View ArticleGoogle Scholar
- DeLuca NA, McCarthy AM, Schaffer PA: Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol. 1985, 56: 558-570.Google Scholar
- Weir JP: Regulation of herpes simplex virus gene expression. Gene. 2001, 271: 117-130. 10.1016/S0378-1119(01)00512-1.View ArticleGoogle Scholar
- Miyatake SI, Tani S, Feigenbaum F, Sundaresan P, Toda H, Narumi O, Kikuchi H, Hashimoto N, Hangai M, Martuza RL, Rabkin SD: Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther. 1999, 6: 564-572. 10.1038/sj.gt.3300861.View ArticleGoogle Scholar
- Yamamura H, Hashio M, Noguchi M, Sugenoya Y, Osakada M, Hirano N, Sasaki Y, Yoden T, Awata N, Araki N, Tatsuta M, Miyatake SI, Takahashi K: Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors. Cancer Res. 2001, 61: 3969-3977.Google Scholar
- Goldstein DJ, Weller SK: Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology. 1988, 166: 41-51. 10.1016/0042-6822(88)90144-4.View ArticleGoogle Scholar
- Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995, 1: 938-943. 10.1038/nm0995-938.View ArticleGoogle Scholar
- Yoon SS, Nakamura H, Carroll NM, Bode BP, Chiocca EA, Tanabe KK: An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. Faseb J. 2000, 14: 301-311.Google Scholar
- Kaname T, Huxley C: Simple and efficient vectors for retrofitting BACs and PACs with mammalian neoR and EGFP marker genes. Gene. 2001, 266: 147-153. 10.1016/S0378-1119(01)00375-4.View ArticleGoogle Scholar
- DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M, Hamper U, DeJong R, Detorie N, Rodriguez R, Haulk T, DeMarzo AM, Piantadosi S, Yu DC, Chen Y, Henderson DR, Carducci MA, Nelson WG, Simons JW: A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001, 61: 7464-7472.Google Scholar
- Ko D, Hawkins L, Yu DC: Development of transcriptionally regulated oncolytic adenoviruses. Oncogene. 2005, 24: 7763-7774. 10.1038/sj.onc.1209048.View ArticleGoogle Scholar
- Kambara H, Okano H, Chiocca EA, Saeki Y: An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res. 2005, 65: 2832-2839. 10.1158/0008-5472.CAN-04-3227.View ArticleGoogle Scholar
- Fukuhara H, Ino Y, Kuroda T, Martuza RL, Todo T: Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res. 2005, 65: 10663-10668. 10.1158/0008-5472.CAN-05-2534.View ArticleGoogle Scholar
- Terada K, Wakimoto H, Tyminski E, Chiocca EA, Saeki Y: Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther. 2006, 13: 705-714. 10.1038/sj.gt.3302717.View ArticleGoogle Scholar
- Saeki Y, Fraefel C, Ichikawa T, Breakefield XO, Chiocca EA: Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther. 2001, 3: 591-601. 10.1006/mthe.2001.0294.View ArticleGoogle Scholar
- Gaudreau A, Hill E, Balfour HHJ, Erice A, Boivin G: Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients. J Infect Dis. 1998, 178: 297-303.View ArticleGoogle Scholar
- Mineta T, Rabkin SD, Martuza RL: Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 1994, 54: 3963-3966.Google Scholar
- Coen DM, Goldstein DJ, Weller SK: Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir. Antimicrob Agents Chemother. 1989, 33: 1395-1399.View ArticleGoogle Scholar
- Stinski MF, Roehr TJ: Activation of the major immediate early gene of human cytomegalovirus by cis-acting elements in the promoter-regulatory sequence and by virus-specific trans-acting components. J Virol. 1985, 55: 431-441.Google Scholar
- Samaniego LA, Neiderhiser L, DeLuca NA: Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J Virol. 1998, 72: 3307-3320.Google Scholar
- Preston CM, Nicholl MJ: Repression of gene expression upon infection of cells with herpes simplex virus type 1 mutants impaired for immediate-early protein synthesis. J Virol. 1997, 71: 7807-7813.Google Scholar
- Kuroda T, Rabkin SD, Martuza RL: Effective treatment of tumors with strong beta-catenin/Tcf activity by transcriptionally-targeted oncolytic herpes simplex virus vector. Cancer Res.
- Addison CL, Hitt M, Kunsken D, Graham FL: Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J Gen Virol. 1997, 78 ( Pt 7): 1653-1661.View ArticleGoogle Scholar
- Baskar JF, Smith PP, Nilaver G, Jupp RA, Hoffmann S, Peffer NJ, Tenney DJ, Colberg-Poley AM, Ghazal P, Nelson JA: The enhancer domain of the human cytomegalovirus major immediate-early promoter determines cell type-specific expression in transgenic mice. J Virol. 1996, 70: 3207-3214.Google Scholar
- Foecking MK, Hofstetter H: Powerful and versatile enhancer-promoter unit for mammalian expression vectors. Gene. 1986, 45: 101-105. 10.1016/0378-1119(86)90137-X.View ArticleGoogle Scholar
- Furth PA, Hennighausen L, Baker C, Beatty B, Woychick R: The variability in activity of the universally expressed human cytomegalovirus immediate early gene 1 enhancer/promoter in transgenic mice. Nucleic Acids Res. 1991, 19: 6205-6208.View ArticleGoogle Scholar
- Goldstein DJ, Weller SK: Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol. 1988, 62: 196-205.Google Scholar
- Umana P, Gerdes CA, Stone D, Davis JR, Ward D, Castro MG, Lowenstein PR: Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nat Biotechnol. 2001, 19: 582-585. 10.1038/89349.View ArticleGoogle Scholar
- Walboomers JM, Schegget JT: A new method for the isolation of herpes simplex virus type 2 DNA. Virology. 1976, 74: 256-258. 10.1016/0042-6822(76)90151-3.View ArticleGoogle Scholar
- Kintner RL, Brandt CR: Rapid small-scale isolation of herpes simplex virus DNA. J Virol Methods. 1994, 48: 189-196. 10.1016/0166-0934(94)90118-X.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.